Positive results from the EPISTOP trial - which is researching the potential benefits of early treatment with vigabatrin to prevent seizures in people living with TSC - have been published. EPISTOP is the first clinical trial to demonstrate a beneficial preventative treatment for any
New research has shown that metformin - a common medicine used in type 2 diabetes - can improve TSC-related epilepsy and reduce the size of SEGAs (subependymal giant cell astrocytoma non-cancerous tumours). The study could have important implications for the way that TSC is
The TSA was delighted to recently host the virtual fundraising event 'In Conversation with Sir David Suchet CBE', in which one of Britain's most loved actors discussed his incredible career across the stage, television and film. For those who were unable to make the
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for Epidyolex® (cannabidiol) as a treatment option for TSC-associated epilepsy in people aged two years and older. The update is a major hurdle crossed in the journey
The London Marathon 2021 will be going virtual, with 50,000 places up for grabs to be part of the world's biggest virtual marathon. You can be part of the excitement, too - take on the challenge for the TSA and make an incredible step
Early bird registration for the International TSC Research Conference 2021 is now open. The conference - aimed at clinicians, researchers and other professionals in TSC - is being proudly organised by the Tuberous Sclerosis Association. Delegates who wish to register can do so here,
The small TSA team has been working flat-out to support the TSC community and enable researchers through this difficult year. Now, we need your help. Covid-19 continues to devastate our fundraising income, right at a time when many in the TSC community
The TSA has received lots of questions from families with children who live TSC, about covid-19 vaccinations for children aged under 16 years old . With the vaccination roll-out well underway, this is understandably a very confusing time for some families. Those talking to
GW Pharmaceuticals has confirmed that the European Commission (EC) has approved Epidyolex® (cannabidiol) as an adjunctive treatment for TSC-related epilepsy in people aged two years and older. The approval marks an important stepping stone in the journey towards the eventual approval and access to
The All Wales Medicines Strategy Group (AWMSG) - who advise Welsh Government about the use, management and prescribing of medicines in Wales - is considering whether to recommend Votubia® (everolimus) for treatment of TSC-associated epilepsy. We need YOUR help to show AWMSG the impact
